Pantherna Therapeutics GmbH. (5/3/24). "Press Release: Company Update. Ansgar Santel Appointed as New CEO". Frankfurt a. M. & Hennigsdorf.

	Organisation	Pantherna Therapeutics GmbH
	Organisation 2	Ascenion GmbH, Office Berlin
	Today	Ascenion GmbH
	Group	Life Science-Stiftung (LifeScience Foundation) (Group)
	Product	mRNA technology
	Product 2	lipid nanoparticle technology (LNP technology)
	Person	Santel, Ansgar (Pantherna Therapeutics 202405– CEO joined 11/21 as Head of Translational Research before Ascenion)
	Person 2	Maass, Gerrit (Pantherna Therapeutics 202201 CFO)

As of today, Ansgar Santel acts as the new Chief Executive Officer and becomes an additional member of the Board of Managing Directors at Pantherna Therapeutics GmbH with Jörg Kaufmann and Gerrit Maass. Ansgar joined Pantherna in November 2021 as Head of Translational Research and Alliance Management. He has a wealth of experience in developing new innovative RNA therapies whilst exhibiting exceptional leadership qualities. We at Pantherna are proud to welcome Ansgar into his new role as CEO and are confident in his commitment to accelerating Pantherna’s innovation and success in the development of impactful RNA therapies.

Contact for additional information:

Dr. Ansgar Santel, CEO
T: +49(0)3302-202 240-0
E-Mail: a.santel@pantherna-therapeutics.com

Record changed: 2024-09-05